XENE Earnings & Financial Statements
Xenon Pharmaceuticals Inc.
$33.90
-$0.52(-1.51%)
24
Overall
--
Value
9
Tech
39
Quality
Market Cap
$3.33B
Volume
1.79M
52W Range
$35.06 - $72.66
Target Price
$71.66
XENE earnings and financial statements: Xenon Pharmaceuticals Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
XENE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $7.50M | - | - | $9.43M | $18.44M |
| Operating income | -$373.07M | -$279.30M | -$214.05M | -$129.14M | -$78.99M |
| EBITDA | -$341.04M | -$234.60M | -$179.41M | -$123.63M | -$78.09M |
| Net income | -$345.91M | -$234.33M | -$182.39M | -$125.37M | -$78.88M |
| EPS (diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $633.16M | $798.14M | $964.80M | $754.15M | $572.01M |
| Total liabilities | $51.40M | $43.24M | $36.88M | $32.65M | $21.97M |
| Shareholders’ equity | $581.76M | $754.90M | $927.92M | $721.50M | $550.03M |
| Cash and equivalents | $199.16M | $142.71M | $148.64M | $57.24M | $175.69M |
| Long-term debt | $6.41M | $7.65M | $9.60M | $9.95M | $7.65M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$279.12M | -$181.39M | -$151.11M | -$101.03M | -$69.50M |
| Capital expenditure | -$799.0K | -$3.08M | -$5.62M | -$2.89M | -$2.05M |
| Free cash flow | -$279.92M | -$184.46M | -$156.73M | -$103.92M | -$71.55M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | XENE | $33.90 | -1.5% | 1.79M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Xenon Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW